Clinical Trial Update: The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating vidicizumab in combination with tirelizumab for breast cancer with low HER2 expression; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tirelizumab (tirelizumab)
• Vidicizumab (Vidicizumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Breast Cancer, Neoadjuvant Therapy | Phase 4 | Status: UNKNOWN